for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Boiron SA

BOIR.PA

Latest Trade

39.65EUR

Change

0.85(+2.19%)

Volume

1,560

Today's Range

38.90

 - 

39.70

52 Week Range

26.75

 - 

44.80

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
38.80
Open
38.90
Volume
1,560
3M AVG Volume
0.20
Today's High
39.70
Today's Low
38.90
52 Week High
44.80
52 Week Low
26.75
Shares Out (MIL)
17.51
Market Cap (MIL)
695.68
Forward P/E
42.33
Dividend (Yield %)
2.65

Latest Developments

More

Boiron Expect Decrease In Sales And Earnings In 2020

Boiron H1 Operating Income Down At 1.5 Million Euros

Boiron H1 Revenue Down EUR 253.6 Mln, Sees Decline In 2020 Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Boiron SA

Boiron SA is a France-based pharmaceutical company engaged in the provision of homeopathic medicines. The Company develops, manufactures and markets single homeopathic medicines and drugs which are in the form of tablets, syrups, single-dose liquids and ointments. It also produces medicines based on trace elements, phytotherapy remedies, food supplements, as well as health and beauty care products. In addition, the Company owns a research center, which works for the development of homeopathy within the world of medicine. Boiron SA operates through a number of subsidiaries, which are based in Italy, Spain, Belgium, the Czech Republic, Slovakia, Russia, Romania, Poland, Hungary, the United States, Canada and Brazil, among others.

Industry

Biotechnology & Drugs

Contact Info

2 avenue de l ouest Lyonnais

69510

France

+33.4.78456100

http://www.boiron.fr/

Executive Leadership

Thierry Boiron

Chairman of the Board of Directors

Valerie Lorentz-Poinsot

Chief Executive Officer, General Manager, Director

Jean-Christophe Michel Bayssat

Deputy Chief Executive Officer (Deputy General Manager), Chief Pharmacist, Pharmaceutical Development Director

Laurence Boiron

Director

Anabelle Flory-Boiron

Director

Key Stats

2.67 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

0.6K

2018

0.6K

2019

0.6K

2020(E)

0.5K
EPS (EUR)

2017

4.250

2018

3.230

2019

2.320

2020(E)

0.937
Price To Earnings (TTM)
17.33
Price To Sales (TTM)
1.26
Price To Book (MRQ)
1.44
Price To Cash Flow (TTM)
6.65
Total Debt To Equity (MRQ)
2.21
LT Debt To Equity (MRQ)
1.63
Return on Investment (TTM)
6.91
Return on Equity (TTM)
5.40

Latest News

Latest News

BRIEF-Boiron Q1 Revenue Up At EUR 156.6 Mln, Sees Drop In 2020 Turnover

* Q1 REVENUE EUR 156.6 MILLION VERSUS EUR 143.3 MILLION YEAR AGO

BRIEF-Boiron FY Net Profit Group Share Down At EUR 40.6 Million Euros

* FY NET PROFIT GROUP SHARE EUR 40.6 MILLION VERSUS EUR 57.5 MILLION YEAR AGO

BRIEF-Boiron Announces Major Reorganisation Plan In France

* THE COMPANY IS TODAY BRINGING TOGETHER TRADE UNIONS TO START DISCUSSIONS ON A DRAFT REORGANISATION IN FRANCE

BRIEF-Boiron Brings Together Trade Unions To Start Discussions On Reorganization Project In France

* BOIRON SA SAYS CO BRINGS TOGETHER TRADE UNIONS TODAY TO START DISCUSSIONS ON REORGANIZATION PROJECT IN FRANCE

BRIEF-Boiron And Lehning Laboratories File Two Appeals Against Homeopathy Health Insurance Orders

* BOIRON AND LEHNING LABORATORIES SAID THEY HAVE FILED TWO APPEALS AT THE CONSEIL D'ETAT AGAINST RULINGS RESTRICTING HEALTH INSURANCE COVERAGE FOR HOMEOPATHIC DRUGS AND MEDICINES

BRIEF-Boiron: HAS Maintains Unfavorable Opinion Regarding Reimbursement Of Homeopathic Medicines

* HAUTE AUTORITE DE SANTE (HAS) HAS MAINTAINED ITS UNFAVORABLE OPINION REGARDING THE REIMBURSEMENT OF HOMEOPATHIC MEDICINES

BRIEF-Boiron Q1 Revenue Broadly Stable At 159.4 Million Euros

* TURNOVER IN Q1 OF 2018 IS ALMOST STABLE (-0.5%) IN COMPARISON TO Q1 OF 2017

BRIEF-Boiron FY Operating Income Down At 125.0 Million Euros

* FY OPERATING INCOME EUR 125.0 MILLION VERSUS EUR 129.7 MILLION YEAR AGO

BRIEF-Boiron FY Revenue up at 617.5 Million Euros

* FY REVENUE EUR 617.5 MILLION VERSUS EUR 614.5 MILLION YEAR AGO

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up